When was Promega founded?

Promega was founded in 1978 and raised its 1st funding round 11 years after it was founded.

Where is Promega located?

Promega is headquartered in Madison, United States.

Which legal entities is Promega associated with?

Promega is associated with PROMEGA BIOTECH INDIA PRIVATE LIMITED and 1 other.

How many employees does Promega have?

As of Oct 31, 2024, Promega has 18 employees, reflecting a 6% year-over-year growth in headcount.

Is Promega a funded company?

Promega is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Oct 1989.

When was the latest funding round of Promega?

Promega's latest funding was a $***** Grant (prize money) round on Jan 01, 2015, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $632M in funding in 2026 to date.

What is the annual revenue of Promega?

Annual revenue of Promega is ₹76.6Cr as on Mar 31, 2025.

Where does Promega rank among its competitors?

Promega ranks 27th amongst 1177 active competitors, of which 100 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was BioLife Solutions, which secured $10.4M in Oct, 2023.

Who are the top competitors of Promega?

Promega's top competitors include Abcam, Illumina and Quanterix. Among them, BioLife Solutions secured the most recent funding round in October, 2023.

Promega - 2026 Company Profile, Funding, Competitors & Financials

Promega is a funded company based in Madison (United States), founded in 1978. It operates as a Provider of genomics, protein analysis and expression, drug discovery, and genetic identification products. Promega has raised an undisclosed amount in funding. The company has 1177 active competitors, including 100 funded and 164 that have exited. Its top competitors include companies like Abcam, Illumina and Quanterix.

Company Details

Provider of genomics, protein analysis, and expression, drug discovery, and genetic identification products. The company claims to hold hundreds of patents in the areas of bioluminescence (engineered luciferases, luciferase reporter vectors, and luciferase substrates), cellular analysis, cell biology, and drug discovery. Their product portfolio includes assays, reagents, and kits to study cell health and energy metabolism, ADMET, cell signaling, immunodetection, products for DNA analysis and forensics, molecular diagnostics products, and more.

Website: promega.in
Social
Email ID: *****@promega.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

1978

Location

Madison, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Jan 01, 2015, $*****

Investors

Venture Investors & 3 more

Ranked

27^th among 1177 active competitors

Annual Revenue

₹76.6Cr as on Mar 31, 2025

Employee Count

18 as on Oct 31, 2024

Similar Companies

Illumina & 648 more

View Promega's full profile

Promega is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Promega Corp. CIN: 391388811 , United States, Active	Dec 31, 1977	-	1521 (As on Dec 31, 2024)	-
PROMEGA BIOTECH INDIA PRIVATE LIMITED CIN: U51102MH2013PTC248556 , India, Active	Sep 25, 2013	$9.06M (As on Mar 31, 2025)	18 (As on Oct 31, 2024)

Promega has raised funding over 4 rounds. Its first funding round was on Oct 1989. Its latest funding round was a Grant (prize money) round on Jan 01, 2015 for $*****. 1 investor participated in its latest round. Promega has 4 institutional investors.

Here is the list of recent funding rounds of Promega:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 01, 2015	7831656	Grant (prize money)	2268788	9386066	5803478	6280384
Jan 01, 2014	2343335	Grant (prize money)	9171744	8931971	5982047	Europa
Sep 30, 2007	3074086	Grant (prize money)	5892342	7044090	3892079	NASA

Access funding benchmarks and valuations. Sign up today!

View details of Promega's funding rounds and investors

Promega's employee count trend

Promega has 18 employees as of Oct 24. The total employee count is 6.0% more than what it was in Oct 23. Here is Promega's employee count trend over the years:

Uncover Promega's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Promega include Abcam, Illumina and Quanterix. Here is the list of Top 10 competitors of Promega, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcam 1998, Cambridge (United Kingdom), Acquired	Developer of biological reagents for life science research	$78.8M	Juno Investment Partners, Martlet Capital ... & 2 others	75/100
2nd	Illumina 1993, San Diego (United States), Public	Developer of technologies for analysis of genetic variation and function	$28M	Chevron Technology Ventures, Dow Chemical Company ... & 32 others	71/100
3rd	Quanterix 2007, Cambridge (United States), Public	Developer of assay kits for ultra-sensitive biomarker detection	$99.5M	T. Rowe Price, Cormorant Asset Management ... & 15 others	71/100
4th	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	Qiming Venture Partners, CTS Capital & 1 others	67/100
5th	BioLife Solutions 1987, Bothell (United States), Public	Developer of cell and gene therapies with the integrity of a single cell	-	-	67/100
6th	Enzo 1976, Farmingdale (United States), Acquired	Life science products and services for research, drug discovery, and manufacturing	$7M	-	67/100
7th	Biocare Medical 1997, Concord (United States), Acquired	Manufacturer of primary antibodies and instruments for immunohistochemistry applications	$85M	Excellere Partners, GHO Capital Partners & 2 others	65/100
8th	Meridian Bioscience 1976, Ohio (United States), Acquired	Molecular diagnostic device and kits	-	JobsOhio, NIH	65/100
9th	MGI 2016, Shenzhen (China), Series B	Provider of gene sequencing instruments, reagents, equipment, and related products	$1B	CoStone Capital, Guotai Junan Securities ... & 12 others	64/100
10th	Mapi Pharma 2008, Ness Ziona (Israel), Series B	Clinical stage pharmaceutical company developing extended release versions of generic drugs.	$60M	aMoon, Shavit Capital & 3 others	62/100
27th	Promega 1978, Madison (United States), Funding Raised	Provider of genomics, protein analysis and expression, drug discovery, and genetic identification products	-	Venture Investors, Baird Capital & 2 others	54/100